Area of research
Pulmonary and Respiratory Medicine · Oncology
Research interest
Research interests include Lung Cancer Treatments and Mutations, Cancer Genomics and Diagnostics, Cancer Immunotherapy and Biomarkers, and RNA modifications and cancer.
The mutagenic forces shaping the genomes of lung cancer in never smokers
Neoadjuvant PD-1 and PD-L1 Blockade With Chemotherapy for Borderline Resectable and Unresectable Stage III Non–Small Cell Lung Cancer
Assessment and classification of sex cord‐stromal tumours of the testis: recommendations from the testicular sex cord‐stromal tumour (<scp>TESST</scp>) group, an Expert Panel of the Genitourinary Pathology Society (<scp>GUPS</scp>) and International Society of Urological Pathology (<scp>ISUP</scp>)
Observer Variation in the Diagnosis of Testicular Sex Cord-Stromal Tumors by a Genitourinary Pathology Society and International Society of Urological Pathology Panel: Paving the Way for a New Classification
Uncovering the role of LINE-1 in the evolution of lung adenocarcinoma
Contrastive learning enhances fairness in pathology artificial intelligence systems
Microbiome analysis of 940 lung cancers in never-smokers reveals lack of clinically relevant associations
A pathology foundation model for cancer diagnosis and prognosis prediction
Deep Learning Model for Predicting Immunotherapy Response in Advanced Non−Small Cell Lung Cancer
Intrapatient variation in PD-L1 expression and tumor mutational burden and the impact on outcomes to immune checkpoint inhibitor therapy in patients with non-small-cell lung cancer
Differentiating Separate Primary Lung Adenocarcinomas From Intrapulmonary Metastases With Emphasis on Pathological and Molecular Considerations: Recommendations From the International Association for the Study of Lung Cancer Pathology Committee
Machine learning for genetics-based classification and treatment response prediction in cancer of unknown primary
Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer
Germline <i>EGFR</i> Mutations and Familial Lung Cancer
Impact of Aneuploidy and Chromosome 9p Loss on Tumor Immune Microenvironment and Immune Checkpoint Inhibitor Efficacy in NSCLC
International Association for the Study of Lung Cancer Study of Reproducibility in Assessment of Pathologic Response in Resected Lung Cancers After Neoadjuvant Therapy
Artificial Intelligence–Powered Assessment of Pathologic Response to Neoadjuvant Atezolizumab in Patients With NSCLC: Results From the LCMC3 Study
Genomic analysis of spermatocytic tumors demonstrates recurrent molecular alterations in cases with malignant clinical behavior
Association of High Tumor Mutation Burden in Non–Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels
Cross-tissue, single-cell stromal atlas identifies shared pathological fibroblast phenotypes in four chronic inflammatory diseases
Predictive Biomarkers for Immunotherapy in Lung Cancer: Perspective From the International Association for the Study of Lung Cancer Pathology Committee
Concurrent TP53 Mutations Facilitate Resistance Evolution in EGFR-Mutant Lung Adenocarcinoma
Association of Machine Learning–Based Assessment of Tumor-Infiltrating Lymphocytes on Standard Histologic Images With Outcomes of Immunotherapy in Patients With NSCLC
Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancer
Defining Morphologic Features of Invasion in Pulmonary Nonmucinous Adenocarcinoma With Lepidic Growth: A Proposal by the International Association for the Study of Lung Cancer Pathology Committee
NSCLC Subtyping in Conventional Cytology: Results of the International Association for the Study of Lung Cancer Cytology Working Group Survey to Determine Specific Cytomorphologic Criteria for Adenocarcinoma and Squamous Cell Carcinoma
Genomic analysis of early-stage lung cancer reveals a role for TP53 mutations in distant metastasis
Clinicopathologic and molecular spectrum of testicular sex cord-stromal tumors not amenable to specific histopathologic subclassification
Myoid gonadal stromal tumours are characterised by recurrent chromosome‐level copy number gains: molecular assessment of a multi‐institutional series
PD-L1 as a biomarker of response to immune-checkpoint inhibitors